ASNS - Actelis Networks Inc.
Actelis Networks Inc. Logo

ASNS - Actelis Networks Inc.

https://actelis.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to treat infectious diseases. The company is headquartered in Waltham, Massachusetts.

52W High
$1.83
52W Low
$0.34

MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.87
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-0.66
EV/Revenue (<3 favorable)
1.03
P/S (TTM) (<3 favorable)
0.93
P/B (<3 favorable)
3.92
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
18.95%
Institutions (25–75% balanced)
4.26%
Shares Outstanding
11,292,100
Float
9,141,200
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
5,265,000
Gross Profit (TTM)
2,663,000
EPS (TTM)
-0.77
Profit Margin (>10% good)
-1.15%
Operating Margin (TTM) (higher better)
-1.88%
ROE (TTM) (>15% strong)
-6.19%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.73
Momentum
Bearish momentum
Value
-0.0298
Previous
-0.0328
Trend
Rising
Signal Cross
No cross

As of
Sep. 11, 2025